Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9831 USD | -0.90% | -6.37% | -89.47% |
2023 | TradeUP Acquisition Corp.(NasdaqCM:UPTD) dropped from NASDAQ Composite Index | CI |
2023 | Estrella Immunopharma, Inc. announced that it has received $10 million in funding | CI |
Valuation
Fiscal Period: December | 2021 | 2022 |
---|---|---|
Capitalization 1 | 57.97 | 60.19 |
Enterprise Value (EV) 1 | 57.49 | 60.7 |
P/E ratio | -129 x | -59.5 x |
Yield | - | - |
Capitalization / Revenue | - | - |
EV / Revenue | - | - |
EV / EBITDA | - | - |
EV / FCF | - | -150,214,084 x |
FCF Yield | - | -0% |
Price to Book | -57.6 x | -10.6 x |
Nbr of stocks (in thousands) | 5,850 | 5,850 |
Reference price 2 | 9.910 | 10.29 |
Announcement Date | 3/29/22 | 3/14/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 |
---|---|---|
Net sales | - | - |
EBITDA | - | - |
EBIT 1 | -0.2491 | -1.57 |
Operating Margin | - | - |
Earnings before Tax (EBT) 1 | -0.2477 | -0.9155 |
Net income 1 | -0.2477 | -0.9961 |
Net margin | - | - |
EPS 2 | -0.0771 | -0.1728 |
Free Cash Flow | - | -0.4041 |
FCF margin | - | - |
FCF Conversion (EBITDA) | - | - |
FCF Conversion (Net income) | - | - |
Dividend per Share | - | - |
Announcement Date | 3/29/22 | 3/14/23 |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 |
---|---|---|
Net Debt 1 | - | 0.51 |
Net Cash position 1 | 0.48 | - |
Leverage (Debt/EBITDA) | - | - |
Free Cash Flow | - | -0.4 |
ROE (net income / shareholders' equity) | - | 61.1% |
ROA (Net income/ Total Assets) | - | -3.53% |
Assets 1 | - | 28.19 |
Book Value Per Share 2 | -0.1700 | -0.9700 |
Cash Flow per Share 2 | 0.0800 | 0.0200 |
Capex | - | - |
Capex / Sales | - | - |
Announcement Date | 3/29/22 | 3/14/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- UPTD Stock
- Financials TRAP ACQU